Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Cited by (516)

Items 101–200 of 516

1. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
   Baoling Ying, Suzanne M. Scheaffer, Bradley M. Whitener, Chieh-Yu Liang, Oleksandr Dmytrenko, Samantha Mackin, Kai Wu, Diana Wing Lee, Laura E. Avena, Zhenlu Chong et al. · 2022 · Cell
2. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies
   Ceri Alan Fielding, Pragati Sabberwal, James C. Williamson, Edward J. D. Greenwood, Thomas W. M. Crozier, Wioleta Milena Zelek, Jeffrey Seow, Carl Graham, Isabella Huettner, Jonathan D. Edgeworth et al. · 2022 · eLife
3. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
   Tingting Li, Wenhui Xue, Qingbing Zheng, Shuo Song, Chuanlai Yang, Hualong Xiong, Sibo Zhang, Minqing Hong, Yali Zhang, Hai Jing Yu et al. · 2021 · Nature Communications
4. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters
   Yangtao Wu, Xiaofen Huang, Lunzhi Yuan, Shaojuan Wang, Yali Zhang, Hualong Xiong, Rirong Chen, Jian Ma, Ruoyao Qi, Meifeng Nie et al. · 2021 · Science Translational Medicine
5. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
   Wei Bu Wang, Yu Liang, Yu Qin Jin, Jing Zhang, Ji Guo Su, Qi Ming Li · 2021 · Journal of Molecular Graphics and Modelling
6. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
   L. Hanke, H. Das, D. Sheward, Laura Perez Vidakovics, E. Urgard, Ainhoa Moliner-Morro, Changil Kim, V. Karl, A. Pankow, Natalie L. Smith et al. · 2022 · Nature Communications
7. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
   Lok Bahadur Shrestha, Nicodemus T. Tedla, Rowena Anne Bull · 2021 · Frontiers in Immunology
8. Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike
   Juliane Brun, Snežana Vasiljević, Bevin Gangadharan, Mario Hensen, Anu V. Chandran, Michelle L. Hill, J. L. Kiappes, Raymond Allen Dwek, Dominic S. Alonzi, Weston B. Struwe et al. · 2021 · ACS Central Science
9. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor-binding domain
   K. Nabel, S. Clark, S. Shankar, Junhua Pan, L. Clark, Pan Yang, A. Coscia, Lindsay G. A. McKay, Haley Varnum, Vesna Brusic et al. · 2021 · Science
10. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
    S. Momsen Reincke, Meng Yuan, Hans‐Christian Kornau, Victor M. Corman, Scott van Hoof, Elisa Sánchez-Sendín, Melanie Ramberger, Wenli Yu, Yuanzi Hua, Henry J. Tien et al. · 2022 · Science
11. Tackling COVID-19 with neutralizing monoclonal antibodies
    Corti, Davide, Purcell, Lisa A., Snell, Gyorgy, Veesler, David · 2021 · Cell
12. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
    E. Rujas, I. Kucharska, Yong-Zi Tan, S. Benlekbir, H. Cui, Tian-Tian Zhao, G. Wasney, P. Budylowski, Furkan Guvenc, J. Newton et al. · 2021 · Nature Communications
13. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates
    Jim B. Boonyaratanakornkit, Chihiro Morishima, Stacy Selke, Danniel Zamora, Sarah A. McGuffin, Adrienne E. Shapiro, Victoria Louise Campbell, Christopher L. McClurkan, Lichen Jing, Robin Gross et al. · 2020 · Journal of Clinical Investigation
14. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines
    John E. Bowen, Young‐Jun Park, Cameron Stewart, Jack T Brown, William K. Sharkey, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Matthew McCallum, M. Alejandra Tortorici et al. · 2022 · Science Immunology
15. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins
    Ha V. Dang, Robert W. Cross, Viktoriya Borisevich, Zachary A. Bornholdt, Brandyn R. West, Yee‐Peng Chan, Chad E. Mire, Sofia Cheliout Da Silva, Antony S. Dimitrov, Lianying Yan et al. · 2021 · Nature Structural & Molecular Biology
16. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
    Fred D. Mast, Peter C. Fridy, Natalia E. Ketaren, Junjie Wang, Erica Y. Jacobs, J. P. Olivier, Tanmoy Sanyal, K. Molloy, Fabian Schmidt, Magda Rutkowska et al. · 2021 · eLife
17. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
    Renhong Yan, Ruoke Wang, Bin Ju, Jinfang Yu, Yuanyuan Zhang, Nan Liu, Jia Wang, Qi Zhang, Peng Chen, Bing Zhou et al. · 2021 · Cell Research
18. Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay
    Changhao Dai, Mingquan Guo, Yanling Wu, Banpeng Cao, Xuejun Wang, Yungen Wu, Hua Kang, Derong Kong, Zhaoqin Zhu, Tianlei Ying et al. · 2021 · Journal of the American Chemical Society
19. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
    Michael S. Piepenbrink, Jun‐Gyu Park, Fatai S. Oladunni, Ashlesha A. Deshpande, Madhubanti Basu, Sanghita Sarkar, Andreas Loos, Jennifer C. Woo, Phillip M. Lovalenti, Derek D. Sloan et al. · 2021 · Cell Reports Medicine
20. Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Biochemistry
21. A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
    Schmitz, Aaron J., Turner, Jackson S., Liu, Zhuoming, Aziati, Ishmael D., Chen, Rita E., Joshi, Astha, Bricker, Traci L., Darling, Tamarand L., Adelsberg, Daniel C., Alsoussi, Wafaa B. et al. · 2021
22. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
    Aaron J. Schmitz, J. Turner, Zhuo-Ming Liu, Julian Q. Zhou, Ishmael D. Aziati, Rita E. Chen, Astha Joshi, T. Bricker, Tamarand L. Darling, Daniel C. Adelsberg et al. · 2021 · Immunity
23. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2
    Cyril Planchais, Ignacio Fernández, Timothée Bruel, Guilherme Dias de Melo, Matthieu Prot, Maxime Beretta, Pablo Guardado‐Calvo, Jérémy Dufloo, Luis Manuel Molinos-Albert, Marija Backović et al. · 2022 · The Journal of Experimental Medicine
24. A rapid cell-free expression and screening platform for antibody discovery
    Andrew C. Hunt, Bastian Vögeli, Ahmed O. Hassan, Laura Guerrero, Weston Kightlinger, Danielle J. Yoesep, Antje Krüger, Madison A. DeWinter, Michael Diamond, Ashty S. Karim et al. · 2023 · Nature Communications
25. An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
    Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijałkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke et al. · 2021 · Science Translational Medicine
26. SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact
    Yui Tik Pang, Atanu Acharya, Diane L. Lynch, Ànna Pavlova, James C. Gumbart · 2022 · Communications Biology
27. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
    Dong, Jinhui, Zost, Seth J., Greaney, Allison J., Starr, Tyler N., Dingens, Adam S., Chen, Elaine C., Chen, Rita E., Case, James Brett, Sutton, Rachel E., Gilchuk, Pavlo et al. · 2021
28. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
    M. Finkelstein, Adam G. Mermelstein, Emma Parker Miller, P. Seth, Erik-Stephane D. Stancofski, D. Fera · 2021 · Viruses
29. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization
    Dhiraj Mannar, James W. Saville, Zehua Sun, Xing Quan Zhu, Michelle M. Martí, Shanti Swaroop Srivastava, Alison Berezuk, Steven Zhou, Katharine S. Tuttle, Michele D. Sobolewski et al. · 2022 · Nature Communications
30. A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
    Laura E. Rosen, M. Alejandra Tortorici, Anna De Marco, Dora Pinto, William B. Foreman, Ashley L. Taylor, Young‐Jun Park, Dana Bohan, Tyson A. Rietz, John M. Errico et al. · 2024 · Cell
31. Animal models for SARS-CoV-2
    Chung-Young Lee, Anice C. Lowen · 2021 · Current Opinion in Virology
32. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
    Micah Rapp, Yicheng Guo, Eswar R. Reddem, Jian Yu, Lihong Liu, Pengfei Wang, Gabriele Cerutti, Phinikoula S. Katsamba, Jude Saber Bimela, Fabiana A. Bahna et al. · 2021 · Cell Reports
33. Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies
    Gennady M. Verkhivker, Luisa Di Paola · 2021 · The Journal of Physical Chemistry B
34. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
    A. Wheatley, P. Pymm, R. Esterbauer, M. Dietrich, W. Lee, D. Drew, Hannah G. Kelly, L. Chan, F. Mordant, K. A. Black et al. · 2021 · Cell Reports
35. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
    Park, Young-Jun, Pinto, Dora, Walls, Alexandra C., Liu, Zhuoming, De Marco, Anna, Benigni, Fabio, Zatta, Fabrizia, Silacci-Fregni, Chiara, Bassi, Jessica, Sprouse, Kaitlin R. et al. · 2022
36. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
    V. Dussupt, R. Sankhala, Letzibeth Mendez-Rivera, Samantha M. Townsley, Fabian Schmidt, L. Wieczorek, Kerri G. Lal, G. Donofrio, Ursula Tran, Nathaniel D. Jackson et al. · 2021 · Nature Immunology
37. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
    Ling Niu, Kathryn N. Wittrock, Gage C. Clabaugh, Vikram Srivastava, Michael W. Cho · 2021 · Frontiers in Immunology
38. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
    Gabriele Cerutti, Micah Rapp, Yicheng Guo, Fabiana A. Bahna, Jude Saber Bimela, Eswar R. Reddem, Jian Yu, Pengfei Wang, Lihong Liu, Yaoxing Huang et al. · 2021 · Structure
39. Structures of Omicron spike complexes and implications for neutralizing antibody development
    Hangtian Guo, Yan Gao, Tinghan Li, Tingting Li, Yuchi Lu, Le Zheng, Yue Liu, Tingting Yang, Feiyang Luo, Shuyi Song et al. · 2022 · Cell Reports
40. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
    Yongjun Sui, Yonas Bekele, Jay A. Berzofsky · 2021 · Pathogens
41. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
    B. B. Banach, G. Cerutti, A. Fahad, Chen-Hsiang Shen, Matheus Oliveira de Souza, P. Katsamba, Y. Tsybovsky, Pengfei Wang, M. Nair, Yao-Xing Huang et al. · 2021 · Cell Reports
42. Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive Vaccines
    Yury Valdés-Balbín, Darielys Santana-Mederos, Françoise Paquet, Sonsire Fernández-Castillo, Yanet Climent, Fabrizio Chiodo, Laura Rodríguez, Belinda Sánchez Ramírez, Kalet León, Tays Hernández et al. · 2021 · ACS Central Science
43. Development and application of therapeutic antibodies against COVID-19
    Lin-jin Ning, H. B. Abagna, Qianhu Jiang, Siqi Liu, Jian Huang · 2021 · International Journal on Biological Sciences
44. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine
    Yupeng Feng, Meng Yuan, John M. Powers, Mengyun Hu, Jennifer E. Munt, Prabhu S. Arunachalam, Sarah R. Leist, Lorenza Bellusci, JungHyun Kim, Kaitlin R. Sprouse et al. · 2023 · Science Translational Medicine
45. Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
    Mary Hongying Cheng, James Krieger, Burak Kaynak, Moshe Arditi, İvet Bahar · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
46. Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies
    Robinson, Sarah A., Raybould, Matthew I. J., Schneider, Constantin, Wong, Wing Ki, Marks, Claire, Deane, Charlotte M. · 2021 · PLOS Computational Biology
47. SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx
    Sang Hoon Kim, Fiona L. Kearns, Mia A. Rosenfeld, Lane William Votapka, Lorenzo Casalino, Micah Papanikolas, Rommie E. Amaro, Ronit Freeman · 2023 · Cell Reports Physical Science
48. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants
    Yinfeng Kang, Cong Sun, Jing Sun, Chu Xie, Zhen Zhuang, Hui-Qin Xu, Zheng Liu, Yihao Liu, Sui Peng, Runyu Yuan et al. · 2022 · Nature Communications
49. Structure and inhibition of SARS-CoV-2 spike refolding in membranes
    Michael W. Grunst, Zhuan Qin, Esteban Dodero‐Rojas, Shilei Ding, Jérémie Prévost, Yaozong Chen, Yanping Hu, Marzena Pazgier, Shenping Wu, Xuping Xie et al. · 2024 · Science
50. Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
    Ronit Rosenfeld, Tal Noy-Porat, Adva Mechaly, Efi Makdasi, Yinon Levy, Ron Alcalay, Reut Falach, Moshe Aftalion, Eyal Epstein, David Gur et al. · 2021 · Nature Communications
51. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
    J. Fedry, Daniel L. Hurdiss, Chunyan Wang, Wen-Tao Li, G. Obal, I. Drulyte, Wenjuan Du, S. Howes, F. V. van Kuppeveld, Friedrich G. Förster et al. · 2021 · Science Advances
52. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
    Wenjuan Du, Daniel L. Hurdiss, Dubravka Drabek, Anna Z. Mykytyn, Franziska Karola Kaiser, Mariana González-Hernández, Diego Muñoz‐Santos, Mart Matthias Lamers, Rien van Haperen, Wentao Li et al. · 2022 · Science Immunology
53. Role of the humoral immune response during COVID-19: guilty or not guilty?
    Melyssa Yaugel-Novoa, Thomas Bourlet, Stéphane Paul · 2022 · Mucosal Immunology
54. NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies
    Teresa R. Wagner, Philipp D. Kaiser, Marius Gramlich, Elena Ostertag, Natalia Ruétalo, Daniel Junker, Julia Häring, Bjoern Traenkle, Matthias Becker, Alex Dulovic et al. · 2021 · EMBO Reports
55. An antibody from single human V H -rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
    Sai Luo, Jun Zhang, Alex J.B. Kreutzberger, Amanda Eaton, Robert J. Edwards, Changbin Jing, Hai‐Qiang Dai, Gregory D. Sempowski, Kenneth D. Cronin, Robert Parks et al. · 2022 · Science Immunology
56. Protective neutralizing epitopes in SARS‐CoV‐2
    Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
57. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
    Bin Ju, Qi Zhang, Ziyi Wang, Zhen Qin Aw, Peng Chen, Bing Zhou, Ruoke Wang, Xiangyang Ge, Qining Lv, Lin Cheng et al. · 2023 · Nature Immunology
58. On the road to ending the COVID-19 pandemic: Are we there yet?
    J. Case, Emma S. Winkler, J. Errico, Michael S. Diamond · 2021 · Virology
59. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
    Andrew R. Crowley, Harini Natarajan, Andrew P. Hederman, Carly A. Bobak, Joshua A. Weiner, Wendy Wieland-Alter, Jiwon Lee, Evan M. Bloch, Aaron A.R. Tobian, Andrew D. Redd et al. · 2022 · eLife
60. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
    Norma A. Valdez-Cruz, E. García-Hernández, C. Espitia, L. Cobos-Marín, C. Altamirano, Carlos G. Bando-Campos, L. F. Cofas-Vargas, E. W. Coronado-Aceves, Ricardo A. González-Hernández, Pablo Hernández-Peralta et al. · 2021 · Microbial Cell Factories
61. Human coronavirus HKU1 recognition of the TMPRSS2 host receptor
    Matthew McCallum, Young‐Jun Park, Cameron Stewart, Kaitlin R. Sprouse, Amin Addetia, Jack T Brown, M. Alejandra Tortorici, Cecily A. Gibson, Emily Wong, Margareta M. Ieven et al. · 2024 · Cell
62. Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Journal of Chemical Theory and Computation
63. SARS-CoV-2 Omicron Variant: ACE2 Binding, Cryo-EM Structure of Spike Protein-ACE2 Complex and Antibody Evasion
    Dhiraj Mannar, James W. Saville, Xing Quan Zhu, Shanti Swaroop Srivastava, Alison Berezuk, Katharine S. Tuttle, Citlali Marquez, Inna Sekirov, Sriram Subramaniam · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
64. Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions
    M. H. Cheng, James M. Krieger, Anupam Banerjee, Yufei Xiang, B. Kaynak, Yi Shi, M. Arditi, I. Bahar · 2022 · iScience
65. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
    Tingting Li, Xiaojian Han, Chenjian Gu, Hangtian Guo, Huajun Zhang, Yingming Wang, Chao Hu, Kai Wang, Fengjiang Liu, Feiyang Luo et al. · 2021 · Nature Communications
66. Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
    Rukmankesh Mehra, Kasper P. Kepp · 2021 · ACS Infectious Diseases
67. A highly potent antibody effective against SARS-CoV-2 variants of concern
    Craig W. Fenwick, Priscilla Turelli, Laurent H. Perez, Céline Pellaton, Line Esteves-Leuenberger, Alex Farina, Jérémy Campos, Erica Lana, Flurin Fiscalini, Charlène Raclot et al. · 2021 · Cell Reports
68. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
    Bart L. Haagmans, Danny Noack, Nisreen M.A. Okba, Wentao Li, Chunyan Wang, Theo M. Bestebroer, Rory D. de Vries, Sander Herfst, Dennis de Meulder, Elwin P. Verveer et al. · 2021 · The Journal of Infectious Diseases
69. Profiles of current COVID-19 vaccines
    Franz Xaver Heinz, Karin Stiasny · 2021 · Wiener klinische Wochenschrift
70. Graphene Transistors for In Vitro Detection of Health Biomarkers
    Changhao Dai, Derong Kong, Chang Chen, Yunqi Liu, Dacheng Wei · 2023 · Advanced Functional Materials
71. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
    William N. Voss, Michael L. Mallory, Patrick O. Byrne, Jeffrey Marchioni, Sean A. Knudson, John M. Powers, Sarah R. Leist, Bernadeta Dadonaite, Douglas R. Townsend, Jessica Kain et al. · 2024 · Cell Reports Medicine
72. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
    Jordan J. Clark, Irene Hoxie, Daniel C. Adelsberg, Iden A. Sapse, Robert Andreata‐Santos, Jeremy S. Yong, Fatima Amanat, Johnstone Tcheou, Ariel J. Raskin, Gagandeep Singh et al. · 2024 · Cell Reports
73. 50 Years of structural immunology
    Ian A. Wilson, Robyn L. Stanfield · 2021 · Journal of Biological Chemistry
74. A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations
    Michelle Verghese, Becky Jiang, Naomi Iwai, Marilyn Mar, Malaya Kumar Sahoo, Fumiko F. Yamamoto, Kenji O. Mfuh, Jacob A. Miller, Hannah Wang, James L. Zehnder et al. · 2021 · Journal of Clinical Microbiology
75. Prospects of Neutralizing Nanobodies Against SARS-CoV-2
    Fangfang Chen, Zhihong Liu, Fan Jiang · 2021 · Frontiers in Immunology
76. Cross-Species Tropism and Antigenic Landscapes of Circulating SARS-CoV-2 Variants
    Yali Zhang, Min Wei, Yangtao Wu, Juan Wang, Yuting Hong, Yang Huang, Lunzhi Yuan, Jian Ma, Kai Wang, Shaojuan Wang et al. · 2021 · Cell Reports
77. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
    Klara Lenart, Fredrika Hellgren, Sebastian Ols, Xianglei Yan, Alberto Cagigi, Rodrigo Arcoverde Cerveira, Inga Patrycja Winge, Jakub Hanczak, Stefan O. Mueller, Edith Jasny et al. · 2022 · Molecular Therapy — Methods & Clinical Development
78. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Ligong Lu, Hui Zhang, Meixiao Zhan, Jun Jiang, Hua Yin, Danielle J. Dauphars, Shi-You Li, Yong Li, You-Wen He · 2020 · Science China Life Sciences
79. Principles of SARS-CoV-2 glycosylation
    Himanshi Chawla, Elisa Fadda, Max Crispin · 2022 · Current Opinion in Structural Biology
80. SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor
    Alice Romagnoli, Mattia D’Agostino, Eleonora Pavoni, Chiara Ardiccioni, Stefano Motta, Paolo Crippa, Giorgio Biagetti, Valentina Notarstefano, Jesmina Rexha, Nunzio Perta et al. · 2022 · Nano Today
81. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
    Kang Wang, Yunlong Cao, Yunjiao Zhou, Jiajing Wu, Zijing Jia, Yaling Hu, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu et al. · 2021 · medRxiv
82. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
    Muecksch, Frauke, Weisblum, Yiska, Barnes, Christopher O., Schmidt, Fabian, Schaefer-Babajew, Dennis, Lorenzi, Julio C C, Flyak, Andrew I, DeLaitsch, Andrew T, Huey-Tubman, Kathryn E, Hou, Shurong et al. · 2021
83. Predicting unseen antibodies’ neutralizability via adaptive graph neural networks
    Jie Zhang, Yishan Du, Pengfei Zhou, Jinru Ding, Shuai Xia, Qian Wang, Feiyang Chen, Mu Zhou, Xuemei Zhang, Wei-Feng Wang et al. · 2022 · Nature Machine Intelligence
84. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
    William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl · 2022 · BioDrugs
85. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
    D. Fu, Guang-Shun Zhang, Yuhui Wang, Zheng Zhang, Heng-Rui Hu, S. Shěn, Jun Wu, Bo Li, Xin Li, Yao-Hui Fang et al. · 2021 · PLoS Biology
86. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology
87. Interaction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations
    Kazuki Akisawa, Ryo Hatada, Koji Okuwaki, Yuji Mochizuki, Kaori Fukuzawa, Yuto Komeiji, Shigenori Tanaka · 2021 · RSC Advances
88. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants
    Cong Sun, Yinfeng Kang, Yuan-Tao Liu, Xiang‐Wei Kong, Hui-Qin Xu, Dan Xiong, Chu Xie, Yihao Liu, Sui Peng, Guo‐Kai Feng et al. · 2022 · Signal Transduction and Targeted Therapy
89. Potent monoclonal antibody–mediated neutralization of a divergent Hendra virus variant
    Zhaoqian Wang, Ha V. Dang, Moushimi Amaya, Yan Xu, Randy Yin, Lianying Yan, Andrew C. Hickey, Edward J. Annand, Bethany A. Horsburgh, Peter A. Reid et al. · 2022 · Proceedings of the National Academy of Sciences
90. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
    Qingrui Huang, Xiaonan Han, Jinghua Yan · 2022 · Emerging Microbes & Infections
91. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
    Ze-Zhong Liu, Wei Xu, Zhenguo Chen, Wang-Jun Fu, Wuqiang Zhan, Yi-Dan Gao, Jie Zhou, Yunjiao Zhou, Jian-Bo Wu, Qian Wang et al. · 2021 · Protein & Cell
92. Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
    Jonathan L. Torres, Gabriel Ozorowski, Emanuele Andreano, Hejun Liu, Jeffrey Copps, Giulia Piccini, Lorena Donnici, Matteo Conti, Cyril Planchais, Delphine Planas et al. · 2022 · Proceedings of the National Academy of Sciences
93. Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice
    Baoling Ying, Suzanne M. Scheaffer, Bradley M. Whitener, Chieh-Yu Liang, Oleksandr Dmytrenko, Samantha Mackin, Kai Wu, Diana Wing Lee, Laura E. Avena, Zhenlu Chong et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
94. Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus
    Jimin Lee, Samantha K. Zepeda, Young‐Jun Park, Ashley L. Taylor, Joel D. Quispe, Cameron Stewart, Elizabeth M. Leaf, Catherine Treichel, Davide Corti, Neil P. King et al. · 2023 · Cell Host & Microbe
95. A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies
    F. Ferrara, M. F. Erasmus, S. D'Angelo, Camila Leal-Lopes, Andre A. R. Teixeira, A. Choudhary, W. Honnen, D. Calianese, De-Li Huang, Linghang Peng et al. · 2022 · Nature Communications
96. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
    Biao Zhou, Runhong Zhou, Bingjie Tang, Jasper Fuk‐Woo Chan, Mengxiao Luo, Qiaoli Peng, Shuofeng Yuan, Hang Liu, Bobo Wing-Yee Mok, Bohao Chen et al. · 2022 · Nature Communications
97. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
    Ling Zhu, Yong‐Qiang Deng, Rong-Rong Zhang, Zhen Cui, Chun-Yun Sun, Changfa Fan, Xiaorui Xing, Weijin Huang, Qi Chen, Na-Na Zhang et al. · 2020 · National Science Review
98. Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
    Dean Gilham, Audrey L. Smith, Li Fu, Dalia Y. Moore, Abenaya Muralidharan, St Patrick Reid, Stephanie C. Stotz, Jan O. Johansson, Michael Sweeney, Norman C.W. Wong et al. · 2021 · Biomedicines
99. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern
    A. Gorchakov, S. Kulemzin, S. Guselnikov, K. Baranov, T. N. Belovezhets, L. Mechetina, O. Volkova, A. Najakshin, N. Chikaev, A. Chikaev et al. · 2021 · Cell Discovery
100. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron
     Siling Wang, Hui Sun, Yali Zhang, Lunzhi Yuan, Yizhen Wang, Tianying Zhang, Shaojuan Wang, Jinlei Zhang, Hai Jing Yu, Hualong Xiong et al. · 2022 · Cell Reports